Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan
June 29, 2020 08:30 ET
|
Aileron Therapeutics, Inc.
-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects -- – In...
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
June 10, 2020 09:53 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by...
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
June 04, 2020 09:15 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a...
Aileron Therapeutics Announces Proposed Public Offering of Common Stock
June 03, 2020 16:01 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron...
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
June 01, 2020 07:00 ET
|
Aileron Therapeutics, Inc.
- - - Observed a protective effect against severe chemotherapy-induced anemia and thrombocytopenia across all dose levels - - - Management to host a conference call and webcast today at 8:30 a.m....
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent
May 27, 2020 08:30 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical...
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 08:30 ET
|
Aileron Therapeutics, Inc.
Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - -Scheduled to report interim results from the...
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
April 22, 2020 08:30 ET
|
Aileron Therapeutics, Inc.
Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - - Final data readout from Phase 1b for both dose optimization and schedule optimization in...
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 30, 2020 16:16 ET
|
Aileron Therapeutics, Inc.
Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung cancer started dosing patients September 2019; interim...
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
December 18, 2019 08:30 ET
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion...